Important Safety Information
IMPORTANT SAFETY INFORMATION/WHAT IS PADCEV®?
IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?
What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:
Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• target lesions (skin reactions that look like rings)
• rash or itching that continues to get worse
• blistering or peeling of the skin
• painful sores or ulcers in mouth or nose, throat, or genital area
• fever or flu-like symptoms
• swollen lymph nodes
See “What are the possible side effects of PADCEV?” for more information about side effects.
Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:
• are currently experiencing numbness or tingling in your hands or feet.
• have a history of high blood sugar or diabetes.
• have liver problems.
• are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.
Females who are able to become pregnant:
• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.
Males with a female sexual partner who is able to become pregnant:
• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.
What are the possible side effects of PADCEV?
PADCEV may cause serious side effects, including:
Skin Reactions. See “What is the most important information I should know about PADCEV?”
High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Nerve problems. Nerve problems called peripheral neuropathy are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
The most common side effects of PADCEV when used alone include:
• rash. See “What is the most important information I should know about PADCEV?”
• changes in liver and kidney function tests
• increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• tiredness
• decreased white blood cell, red blood cell, and platelet counts
• hair loss
• decreased appetite
• diarrhea
• decreased sodium, phosphate and protein (albumin) in the blood
• nausea
• itching
• change in sense of taste
• increased uric acid in the blood
• increased lipase (a test done to check your pancreas)
• decreased weight
• dry skin
If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
The most common side effects of PADCEV when used in combination with pembrolizumab include:
• increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• changes in liver and kidney function tests
• rash. See “What is the most important information I should know about PADCEV?”
• decreased red blood cell and white blood cell counts
• tiredness
• decreased sodium, phosphate and protein (albumin) in the blood
• increased lipase (a test done to check your pancreas)
• hair loss
• decreased weight
• diarrhea
• itching
• decreased appetite
• nausea
• change in sense of taste
• urinary tract infection
• constipation
• increased or decreased potassium
• increased calcium in the blood
• swelling of the arms, hands, legs and feet
• dry eye. See “Eye problems”
• dizziness
• joint aches
• dry skin
PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of PADCEV.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:
• have received an immunotherapy medicine and chemotherapy that contains platinum, or
• are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:
• are not able to receive a chemotherapy that contains the medicine cisplatin.
It is not known if PADCEV is safe and effective in children.
PADCEV with pembrolizumab was FDA approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm the clinical benefit.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
You are leaving PADCEV.com
By clicking “go to link” below, you are leaving an Astellas Pharma US, Inc. and Seagen Inc. website. Astellas Pharma US, Inc. and Seagen Inc. are not responsible for the information or services on any third-party sites.
This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Astellas Pharma US, Inc. and/or Seagen Inc. of the site, its contents, or the owner of the site. Please review the privacy policy and terms of use of the site to understand how your information will be processed.
Thank you for visiting our site.
Cancel
WHAT IS PADCEV®
(enfortumab vedotin-ejfv)?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.
PADCEV may be used alone if you:
• have received an immunotherapy medicine and chemotherapy that contains platinum, or
• are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:
• are not able to receive a chemotherapy that contains the medicine cisplatin.
PADCEV with pembrolizumab was FDA-approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm the clinical benefit.
• Skin reactions
• High blood sugar (hyperglycemia)
• Lung problems
• Nerve problems
• Eye problems
• Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation)
Learn more information about serious side effects in the PADCEV Patient Information.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
If your healthcare provider prescribes PADCEV in combination with pembrolizumab (Keytruda®) for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
Be sure to report any symptoms when you first experience them. Tell your healthcare team if any of your symptoms worsen. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
Back to top
Important Safety Information
IMPORTANT SAFETY INFORMATION/WHAT IS PADCEV®?
IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?
What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:
Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• target lesions (skin reactions that look like rings)
• rash or itching that continues to get worse
• blistering or peeling of the skin
• painful sores or ulcers in mouth or nose, throat, or genital area
• fever or flu-like symptoms
• swollen lymph nodes
See “What are the possible side effects of PADCEV?” for more information about side effects.
Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:
• are currently experiencing numbness or tingling in your hands or feet.
• have a history of high blood sugar or diabetes.
• have liver problems.
• are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.
Females who are able to become pregnant:
• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.
Males with a female sexual partner who is able to become pregnant:
• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.
What are the possible side effects of PADCEV?
PADCEV may cause serious side effects, including:
Skin Reactions. See “What is the most important information I should know about PADCEV?”
High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Nerve problems. Nerve problems called peripheral neuropathy are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
The most common side effects of PADCEV when used alone include:
• rash. See “What is the most important information I should know about PADCEV?”
• changes in liver and kidney function tests
• increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• tiredness
• decreased white blood cell, red blood cell, and platelet counts
• hair loss
• decreased appetite
• diarrhea
• decreased sodium, phosphate and protein (albumin) in the blood
• nausea
• itching
• change in sense of taste
• increased uric acid in the blood
• increased lipase (a test done to check your pancreas)
• decreased weight
• dry skin
If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
The most common side effects of PADCEV when used in combination with pembrolizumab include:
• increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• changes in liver and kidney function tests
• rash. See “What is the most important information I should know about PADCEV?”
• decreased red blood cell and white blood cell counts
• tiredness
• decreased sodium, phosphate and protein (albumin) in the blood
• increased lipase (a test done to check your pancreas)
• hair loss
• decreased weight
• diarrhea
• itching
• decreased appetite
• nausea
• change in sense of taste
• urinary tract infection
• constipation
• increased or decreased potassium
• increased calcium in the blood
• swelling of the arms, hands, legs and feet
• dry eye. See “Eye problems”
• dizziness
• joint aches
• dry skin
PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of PADCEV.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:
• have received an immunotherapy medicine and chemotherapy that contains platinum, or
• are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:
• are not able to receive a chemotherapy that contains the medicine cisplatin.
It is not known if PADCEV is safe and effective in children.
PADCEV with pembrolizumab was FDA approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm the clinical benefit.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
Important Safety Information
IMPORTANT SAFETY INFORMATION/WHAT IS PADCEV®?
IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?
What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:
Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• target lesions (skin reactions that look like rings)
• rash or itching that continues to get worse
• blistering or peeling of the skin
• painful sores or ulcers in mouth or nose, throat, or genital area
• fever or flu-like symptoms
• swollen lymph nodes
See “What are the possible side effects of PADCEV?” for more information about side effects.
Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:
• are currently experiencing numbness or tingling in your hands or feet.
• have a history of high blood sugar or diabetes.
• have liver problems.
• are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.
Females who are able to become pregnant:
• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.
Males with a female sexual partner who is able to become pregnant:
• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.
What are the possible side effects of PADCEV?
PADCEV may cause serious side effects, including:
Skin Reactions. See “What is the most important information I should know about PADCEV?”
High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Nerve problems. Nerve problems called peripheral neuropathy are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
The most common side effects of PADCEV when used alone include:
• rash. See “What is the most important information I should know about PADCEV?”
• changes in liver and kidney function tests
• increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• tiredness
• decreased white blood cell, red blood cell, and platelet counts
• hair loss
• decreased appetite
• diarrhea
• decreased sodium, phosphate and protein (albumin) in the blood
• nausea
• itching
• change in sense of taste
• increased uric acid in the blood
• increased lipase (a test done to check your pancreas)
• decreased weight
• dry skin
If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
The most common side effects of PADCEV when used in combination with pembrolizumab include:
• increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• changes in liver and kidney function tests
• rash. See “What is the most important information I should know about PADCEV?”
• decreased red blood cell and white blood cell counts
• tiredness
• decreased sodium, phosphate and protein (albumin) in the blood
• increased lipase (a test done to check your pancreas)
• hair loss
• decreased weight
• diarrhea
• itching
• decreased appetite
• nausea
• change in sense of taste
• urinary tract infection
• constipation
• increased or decreased potassium
• increased calcium in the blood
• swelling of the arms, hands, legs and feet
• dry eye. See “Eye problems”
• dizziness
• joint aches
• dry skin
PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of PADCEV.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:
• have received an immunotherapy medicine and chemotherapy that contains platinum, or
• are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:
• are not able to receive a chemotherapy that contains the medicine cisplatin.
It is not known if PADCEV is safe and effective in children.
PADCEV with pembrolizumab was FDA approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm the clinical benefit.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
Important Safety Information
IMPORTANT SAFETY INFORMATION/WHAT IS PADCEV®?
IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?
What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:
Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• target lesions (skin reactions that look like rings)
• rash or itching that continues to get worse
• blistering or peeling of the skin
• painful sores or ulcers in mouth or nose, throat, or genital area
• fever or flu-like symptoms
• swollen lymph nodes
See “What are the possible side effects of PADCEV?” for more information about side effects.
Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:
• are currently experiencing numbness or tingling in your hands or feet.
• have a history of high blood sugar or diabetes.
• have liver problems.
• are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.
Females who are able to become pregnant:
• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.
Males with a female sexual partner who is able to become pregnant:
• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.
What are the possible side effects of PADCEV?
PADCEV may cause serious side effects, including:
Skin Reactions. See “What is the most important information I should know about PADCEV?”
High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Nerve problems. Nerve problems called peripheral neuropathy are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
The most common side effects of PADCEV when used alone include:
• rash. See “What is the most important information I should know about PADCEV?”
• changes in liver and kidney function tests
• increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• tiredness
• decreased white blood cell, red blood cell, and platelet counts
• hair loss
• decreased appetite
• diarrhea
• decreased sodium, phosphate and protein (albumin) in the blood
• nausea
• itching
• change in sense of taste
• increased uric acid in the blood
• increased lipase (a test done to check your pancreas)
• decreased weight
• dry skin
If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
The most common side effects of PADCEV when used in combination with pembrolizumab include:
• increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• changes in liver and kidney function tests
• rash. See “What is the most important information I should know about PADCEV?”
• decreased red blood cell and white blood cell counts
• tiredness
• decreased sodium, phosphate and protein (albumin) in the blood
• increased lipase (a test done to check your pancreas)
• hair loss
• decreased weight
• diarrhea
• itching
• decreased appetite
• nausea
• change in sense of taste
• urinary tract infection
• constipation
• increased or decreased potassium
• increased calcium in the blood
• swelling of the arms, hands, legs and feet
• dry eye. See “Eye problems”
• dizziness
• joint aches
• dry skin
PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of PADCEV.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:
• have received an immunotherapy medicine and chemotherapy that contains platinum, or
• are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:
• are not able to receive a chemotherapy that contains the medicine cisplatin.
It is not known if PADCEV is safe and effective in children.
PADCEV with pembrolizumab was FDA approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm the clinical benefit.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-1008-PM 07/23
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM,
is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.
© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-1008-PM 07/23
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.
© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-1008-PM 07/23
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM,
is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.
© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-1008-PM 07/23
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.
